{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T15:34:20Z","timestamp":1757777660332,"version":"3.44.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"15-16","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009898","name":"Beckett-Fonden","doi-asserted-by":"publisher","award":["20-2-6128"],"award-info":[{"award-number":["20-2-6128"]}],"id":[{"id":"10.13039\/501100009898","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021817","name":"Knud og Edith Eriksens Mindefond","doi-asserted-by":"publisher","award":["n.a."],"award-info":[{"award-number":["n.a."]}],"id":[{"id":"10.13039\/501100021817","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006356","name":"University of Southern Denmark","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006356","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Summary<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Low socioeconomic status is associated with disadvantages in health outcomes and delivery of medical care in patients with Inflammatory Bowel Disease (IBD). Inequality in the utilisation of biologic treatment is largely unexplored.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aim<\/jats:title>\n            <jats:p>To explore the potential association of socioeconomic status and time to first biologic treatment in a\u00a0population-based IBD cohort.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>All 37,380 IBD incidences between 2000 and 2017 from the Danish National Patient Register were identified and linked to socioeconomic information including educational level, income and occupational status at diagnosis. Hazard ratios for receiving biologic treatment among socioeconomic groups were estimated using Cox proportional hazard regression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>No difference in time between diagnosis and biologic treatment initiation was found comparing patients with upper secondary, vocational, or academic education to those with lower secondary education in patients with IBD. Patients with Crohn\u2019s disease in the two highest income quartiles received biologic treatment earlier (HR 1.16; 95% CI: 1.04; 1.30 &amp; HR 1.15; 95% CI: 1.03; 1.30). An elevated treatment rate was found for persons with \u201cother\u201d occupational status (unspecified source of income) compared to employed persons in patients with ulcerative colitis (HR 1.36; 95% CI: 1.11; 1.66), but not in patients with Crohn\u2019s disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study revealed equal initiation of biologic treatment among patients with IBD across different educational background, income and occupational status. However, results are limited to a\u00a0setting with free universal healthcare coverage and treatment needs should be considered and addressed in future research.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00508-024-02376-8","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T20:02:21Z","timestamp":1716580941000},"page":"463-469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Socioeconomic equality in initiation of biologic treatment in Danish patients with inflammatory bowel disease"],"prefix":"10.1007","volume":"137","author":[{"given":"Sofie Ronja","family":"Petersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Fogh Rasmussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnete","family":"Overgaard Donskov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lau Caspar","family":"Thygesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim Rose","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Juel Ahrenfeldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vibeke","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"issue":"10080","key":"2376_CR1","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro\u00a0R, Mehandru\u00a0S, Allen\u00a0PB, Peyrin-Biroulet\u00a0L, Colombel\u00a0J\u2011F. Ulcerative colitis. Lancet. 2017;389(10080):1756\u201370.","journal-title":"Lancet"},{"issue":"10080","key":"2376_CR2","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres\u00a0J, Mehandru\u00a0S, Colombel\u00a0JF, Peyrin-Biroulet\u00a0L. Crohn\u2019s disease. Lancet. 2017;389(10080):1741\u201355.","journal-title":"Lancet"},{"issue":"1","key":"2376_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","volume":"5","author":"S Alatab","year":"2020","unstructured":"Alatab\u00a0S, Sepanlou\u00a0SG, Ikuta\u00a0K, Vahedi\u00a0H, Bisignano\u00a0C, Saeid Safiri\u00a0AS, et\u00a0al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a\u00a0systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17\u201330.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"2376_CR4","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/ecco-jcc\/jjab029","volume":"15","author":"M Zhao","year":"2021","unstructured":"Zhao\u00a0M, G\u00f6nczi\u00a0L, Lakatos\u00a0PL, Burisch\u00a0J. The Burden of Inflammatory Bowel Disease in Europe in 2020. J\u00a0Crohn\u2019s Colitis. 2021;15(9):1573\u201387.","journal-title":"J Crohn\u2019s Colitis"},{"key":"2376_CR5","doi-asserted-by":"publisher","first-page":"765474","DOI":"10.3389\/fmed.2021.765474","volume":"8","author":"Z Cai","year":"2021","unstructured":"Cai\u00a0Z, Wang\u00a0S, Li\u00a0J. Treatment of Inflammatory Bowel Disease: A\u00a0Comprehensive Review. Front Med. 2021;8:765474.","journal-title":"Front Med"},{"key":"2376_CR6","unstructured":"Authority DH. Social ulighed i sundhed og sygdom Copenhagen: National Institute of. Public Health. 2020;."},{"issue":"12","key":"2376_CR7","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.14309\/ajg.0000000000000794","volume":"115","author":"CN Bernstein","year":"2020","unstructured":"Bernstein\u00a0CN, Walld\u00a0R, Marrie\u00a0RA. Social Determinants of Outcomes in Inflammatory Bowel Disease. Am J Gastroenterol. 2020;115(12):2036\u201346.","journal-title":"Am J Gastroenterol"},{"issue":"sup2","key":"2376_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10810730.2016.1201175","volume":"21","author":"K Friis","year":"2016","unstructured":"Friis\u00a0K, Lasgaard\u00a0M, Rowlands\u00a0G, Osborne\u00a0RH, Maindal\u00a0HT. Health Literacy Mediates the Relationship Between Educational Attainment and Health Behavior: A\u00a0Danish Population-Based Study. J\u00a0Health Commun. 2016;21(sup2):54\u201360.","journal-title":"J Health Commun"},{"issue":"9596","key":"2376_CR9","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm\u00a0E, Altman\u00a0DG, Egger\u00a0M, Pocock\u00a0SJ, G\u00f8tzsche\u00a0PC, Vandenbroucke\u00a0JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137.","journal-title":"Lancet"},{"issue":"8","key":"2376_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","volume":"29","author":"M Schmidt","year":"2014","unstructured":"Schmidt\u00a0M, Pedersen\u00a0L, S\u00f8rensen\u00a0HT. The Danish Civil Registration System as a\u00a0tool in epidemiology. Eur J Epidemiol. 2014;29(8):541\u20139.","journal-title":"Eur J Epidemiol"},{"key":"2376_CR11","doi-asserted-by":"crossref","unstructured":"Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39(7 Suppl):22\u20135.","DOI":"10.1177\/1403494810387965"},{"key":"2376_CR12","doi-asserted-by":"crossref","unstructured":"Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. Scand J Public Health. 2011;39(7_suppl):103\u20135.","DOI":"10.1177\/1403494811405098"},{"key":"2376_CR13","doi-asserted-by":"crossref","unstructured":"Jensen VM, Rasmussen AW. Danish education registers. Scand J Public Health. 2011;39(7_suppl):91\u20134.","DOI":"10.1177\/1403494810394715"},{"key":"2376_CR14","doi-asserted-by":"crossref","unstructured":"Petersson F, Baadsgaard M, Thygesen LC. Danish registers on personal labour market affiliation. Scand J Public Health. 2011;39(7_suppl):95\u20138.","DOI":"10.1177\/1403494811408483"},{"key":"2376_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP.S91125","volume":"7","author":"M Schmidt","year":"2015","unstructured":"Schmidt\u00a0M, Schmidt\u00a0SA, Sandegaard\u00a0JL, Ehrenstein\u00a0V, Pedersen\u00a0L, S\u00f8rensen\u00a0HT. The Danish National Patient Registry: a\u00a0review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449\u201390.","journal-title":"Clin Epidemiol"},{"key":"2376_CR16","unstructured":"OECD, European Union, UNESCO Institute for Statistics. ISCED 2011 Operational Manual: Guidelines for Classifying National Education Programmes and Related Qualifications. OECD Publishing; 2015."},{"key":"2376_CR17","doi-asserted-by":"crossref","unstructured":"Asscher VER, Biemans VBC, Pierik MJ, Dijkstra G, L\u00f6wenberg M, Van Der MS, et\u00a0al. Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease\u2014a prospective multicentre cohort study. Aliment Pharmacol Ther. 2020;.","DOI":"10.1111\/apt.16073"},{"issue":"22","key":"2376_CR18","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.3748\/wjg.v17.i22.2723","volume":"17","author":"ALS Rom\u00e1n","year":"2011","unstructured":"Rom\u00e1n\u00a0ALS. Comorbidity in inflammatory bowel disease. World J Gastroenterol. 2011;17(22):2723.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"2376_CR19","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.semarthrit.2004.11.006","volume":"34","author":"MC Hochberg","year":"2005","unstructured":"Hochberg\u00a0MC, Lebwohl\u00a0MG, Plevy\u00a0SE, Hobbs\u00a0KF, Yocum\u00a0DE. The benefit\/risk profile of TNF-blocking agents: findings of a\u00a0consensus panel. Semin Arthritis Rheum. 2005;34(6):819\u201336.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"2376_CR20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ Vanderweele","year":"2017","unstructured":"Vanderweele\u00a0TJ, Ding\u00a0P. Sensitivity Analysis in Observational Research: Introducing the E\u2011Value. Ann Intern Med. 2017;167(4):268.","journal-title":"Ann Intern Med"},{"key":"2376_CR21","doi-asserted-by":"publisher","DOI":"10.1787\/3c8385d0-en","volume-title":"Health for Everyone?","author":"OECD","year":"2019","unstructured":"OECD. Health for Everyone? Paris: OECD Health Policy Studies, OECD Publishing; 2019."},{"issue":"4","key":"2376_CR22","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/bcp.13494","volume":"84","author":"O Gendelman","year":"2018","unstructured":"Gendelman\u00a0O, Weitzman\u00a0D, Rosenberg\u00a0V, Shalev\u00a0V, Chodick\u00a0G, Amital\u00a0H. Characterization of adherence and persistence profile in a\u00a0real-life population of patients treated with adalimumab. Br J Clin Pharmacol. 2018;84(4):786\u201395.","journal-title":"Br J Clin Pharmacol"},{"key":"2376_CR23","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/ibd.21482","volume":"17(6","author":"S Nahon","year":"2011","unstructured":"Nahon\u00a0S, Lahmek\u00a0P, Saas\u00a0C, Durance\u00a0C, Olympie\u00a0A, Lesgourgues\u00a0B, et\u00a0al. Socioeconomic and psychological factors associated with nonadherence to treatment in inflammatory bowel disease patients: results of the ISSEO survey. Inflamm Bowel Dis. 2011;17(6:1270\u20136.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"2376_CR24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/jgh3.12160","volume":"3","author":"SK Tomar","year":"2019","unstructured":"Tomar\u00a0SK, Kedia\u00a0S, Singh\u00a0N, Upadhyay\u00a0AD, Kamat\u00a0N, Bopanna\u00a0S, et\u00a0al. Higher education, professional occupation, and upper socioeconomic status are associated with lower adherence to medications in patients with inflammatory bowel disease. Jgh Open. 2019;3(4):302\u20139.","journal-title":"Jgh Open"},{"issue":"3","key":"2376_CR25","first-page":"215","volume":"11","author":"MV Lenti","year":"2017","unstructured":"Lenti\u00a0MV, Selinger\u00a0CP. Medication non-adherence in adult patients affected by inflammatory bowel disease: a\u00a0critical review and update of the determining factors, consequences and possible interventions. Expert Rev Gastroenterol Hepatol. 2017;11(3):215\u201326.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"5","key":"2376_CR26","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/14034940600554644","volume":"34","author":"J Gundgaard","year":"2006","unstructured":"Gundgaard\u00a0J. Income-related inequality in utilization of health services in Denmark: Evidence from Funen County. Scand J Public Health. 2006;34(5):462\u201371.","journal-title":"Scand J Public Health"},{"key":"2376_CR27","doi-asserted-by":"crossref","unstructured":"Krarup AL, Larsen L, Nayeb AB, Gr\u00f8ntved S, Paaske Johnsen S, Esbj\u00f8rn M, et\u00a0al. Less prevalent use of biologics for inflammatory bowel disease in patients from Non-Academic hospitals\u2014a\u00a0Danish register-based study of a\u00a0region with 580,000 citizens. Scand J Gastroenterol. 2022; 1\u20136.","DOI":"10.1080\/00365521.2022.2143726"},{"issue":"4","key":"2376_CR28","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/MOG.0b013e32832b764b","volume":"25","author":"CA Siegel","year":"2009","unstructured":"Siegel\u00a0CA. Making therapeutic decisions in inflammatory bowel disease: the role of patients. Curr Opin Gastroenterol. 2009;25(4):334\u20138.","journal-title":"Curr Opin Gastroenterol"},{"key":"2376_CR29","unstructured":"Dahlerup JF, Fallingborg J, Hvas CL, Kjeldsen J, Munck LK, Nordgaard-Lassen I, et\u00a0al. Behandling af kronisk inflammatorisk tarmsygdom med biologiske l\u00e6gemidler2019 20 Apr 2022."},{"issue":"10","key":"2376_CR30","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1080\/00365521.2020.1807598","volume":"55","author":"B Lo","year":"2020","unstructured":"Lo\u00a0B, Vind\u00a0I, Vester-Andersen\u00a0MK, Burisch\u00a0J. Validation of ulcerative colitis and Crohn\u2019s disease and their phenotypes in the Danish National Patient Registry using a\u00a0population-based cohort. Scand J Gastroenterol. 2020;55(10):1171\u20135.","journal-title":"Scand J Gastroenterol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02376-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-024-02376-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02376-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T19:56:39Z","timestamp":1757102199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-024-02376-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":30,"journal-issue":{"issue":"15-16","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2376"],"URL":"https:\/\/doi.org\/10.1007\/s00508-024-02376-8","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"type":"print","value":"0043-5325"},{"type":"electronic","value":"1613-7671"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"assertion":[{"value":"24 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.R.\u00a0Petersen, N.\u00a0Fogh Rasmussen, A.\u00a0Overgaard Donskov, L.C.\u00a0Thygesen, K.R.\u00a0Olsen, L.\u00a0Juel Ahrenfeldt and V.\u00a0Andersen declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was register-based and approved by the Danish Data Protection Agency (19\/46593) and the Danish Patient Safety Authority. According to Danish law, the study does not need approval from the local Ethics Committee or Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}